27 Jul 2017
N+1 Singer - Oxford BioMedica - Forecasts updated for new Novartis supply agreement
We have updated our forecasts on Oxford BioMedica this morning following the new Novartis supply agreement (announced 6th July). The new supply agreement was established in anticipation of the potential commercial launch of CTL019 for the treatment of acute lymphoblastic leukaemia (ALL), which was recently unanimously recommended for approval by the FDA advisory committee. We continue to look forward to regulatory approval of CTL019, on which Oxford BioMedica is eligible to a royalty on sales. W ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Oxford BioMedica - Forecasts updated for new Novartis supply agreement
Oxford BioMedica plc (OXB:LON) | 218 7.6 1.6% | Mkt Cap: 218.3m
- Published:
27 Jul 2017 -
Author:
Sheena Berry -
Pages:
3
We have updated our forecasts on Oxford BioMedica this morning following the new Novartis supply agreement (announced 6th July). The new supply agreement was established in anticipation of the potential commercial launch of CTL019 for the treatment of acute lymphoblastic leukaemia (ALL), which was recently unanimously recommended for approval by the FDA advisory committee. We continue to look forward to regulatory approval of CTL019, on which Oxford BioMedica is eligible to a royalty on sales. W ....